x
Volume 41 Issue 4
Dec.  2018
Turn off MathJax
Article Contents
Jie GONG, Xiaofei XU. Research progress of MR functional imaging in primary hepatic caminoma[J]. Journal of Molecular Imaging, 2018, 41(4): 461-464. doi: 10.12122/j.issn.1674-4500.2018.04.10
Citation: Jie GONG, Xiaofei XU. Research progress of MR functional imaging in primary hepatic caminoma[J]. Journal of Molecular Imaging, 2018, 41(4): 461-464. doi: 10.12122/j.issn.1674-4500.2018.04.10

Research progress of MR functional imaging in primary hepatic caminoma

doi: 10.12122/j.issn.1674-4500.2018.04.10
  • Received Date: 2018-09-14
  • Publish Date: 2018-11-01
  • Primary Hepatic Caminoma is one of the most common malignant tumors in the world. The prevalence rate of our country is higher than that of Europe,the United States and other developed countries.It seriously impacts the life quality of patients and their families. At present, imaging examination of primary liver cancer mainly includes B ultrasound, CT, DSA and MR. B ultrasound is cheap, easy to operate and sensitive to soft tissue lesions. But it is limited by the experience and meticulous degree of the examiner and with less accurate for the diagnosis of early small liver cancer (diameter <1 cm). CT has a high spatial and density resolution.But CT has radiation and false positive. DSA is a invasive examination. MR imaging is non-invasive, and has no radiation with high resolution of soft tissue. It can carry out multi parameter, multi-directional imaging and various functional imaging. It is widely used in clinical application. This article reviews the application of MR imaging in diagnosis, differential diagnosis and evaluation of the therapeutic effect of primary liver cancer.

     

  • loading
  • [1]
    Parkin DM. Global cancer statistics in the year 2000[J]. Lancet oncol, 2001, 2(9): 533-43 doi: 10.1016/S1470-2045(01)00486-7
    [2]
    中华人民共和国卫生和计划生育委员会医政医管局. 原发性肝癌诊疗规范(2017年版)[J]. 中华消化外科杂志, 2017, 16(7): 635-47 doi: 10.3760/cma.j.issn.1673-9752.2017.07.001
    [3]
    蒙秋华, 龙莉玲, 黄仲奎, 等. 原发性肝癌的MRI诊断价值[J]. 实用放射学杂志, 2006, 22(1): 45-9 doi: 10.3969/j.issn.1002-1671.2006.01.013
    [4]
    Ebara M, Ohto M, Watanabe Y, et al. Diagnosis of small hepatocellular carcinoma: correlation of Mr imaging and tumor histologic studies[J]. Radiology, 1986, 159(2): 371-7 doi: 10.1148/radiology.159.2.3008213
    [5]
    边 杰, 王之章. 原发性肝癌的磁共振成像及病理对照研究[J]. 中华放射学杂志, 1993, 40(2): 86-90
    [6]
    周康荣, 陈祖望. 体部磁共振成像[M]. 上海: 上海医科大学出版社, 2000: 1005-201.
    [7]
    Pang EH, Harris AC, Chang SD. Approach to the solitary liver lesion: imaging and when to biopsy[J]. Canad Associat Radiol J, 2016, 67(2): 130-48 doi: 10.1016/j.carj.2015.07.005
    [8]
    郭启勇, 辛 军, 张 新, 等. MRI水扩散加权成像分子机理研究进展[J]. 中国临床医学影像杂志, 2013, 24(7): 496-500 doi: 10.3969/j.issn.1008-1062.2013.07.014
    [9]
    曾洪武, 王培军. 磁共振扩散加权与弥散张量成像原理分析及比较[J]. 中国医学影像技术, 2005, 21(12): 1945-7 doi: 10.3321/j.issn:1003-3289.2005.12.042
    [10]
    Tokgoz O, Unlu E, Unal I, et al. Diagnostic value of diffusion weighted MRI and ADC in differential diagnosis of cavernous hemangioma of the liver[J]. Afr Health Sci, 2016, 16(1): 227-33 doi: 10.4314/ahs.v16i1.30
    [11]
    Li R, Wu G, Wang R. Application values of 3.0T magnetic resonance diffusion weighted imaging for distinguishing liver malignant tumors and benign lesions[J]. Oncol Lett, 2018, 15(2): 2091-6
    [12]
    胡伟卓, 刘忠虎, 秦红娟, 等. 不同分化程度的原发性肝癌MRI初步临床研究[J]. 现代生物医学进展, 2017, 17(26): 5074-8
    [13]
    Woo S, Lee JM, Yoon JH, et al. Intravoxel incoherent motion diffusion-weighted Mr imaging of hepatocellular carcinoma: correlation with enhancement degree and histologic grade[J]. Radiology, 2014, 270(3): 758-67 doi: 10.1148/radiol.13130444
    [14]
    Catalano OA, Choy G, Zhu A, et al. Differentiation of malignant thrombus from bland thrombus of the portal vein in patients with hepatocellular carcinoma: application of diffusion-weighted Mr imaging[J]. Radiology, 2010, 254(1): 154-62 doi: 10.1148/radiol.09090304
    [15]
    沈继明, 张学琴, 梁宏伟, 等. DWI、T2WI及MR动态增强扫描成像对不同分化小肝癌定量研究[J]. 中国CT和MRI杂志, 2016, 13(2): 75-7 doi: 10.3969/j.issn.1672-5131.2016.02.024
    [16]
    Petra GK, Eric J. Diffusion weighted imaging in the liver[J]. World J Gastroenterol, 2010, 16(13): 1567-76 doi: 10.3748/wjg.v16.i13.1567
    [17]
    Tajima T, Honda H, Taguchi K, et al. Sequential hemodynamic change in hepatocellular carcinoma and dysplastic nodules: CT angiography and pathologic correlation[J]. Am J Roentgenol, 2002, 178(4): 885-97 doi: 10.2214/ajr.178.4.1780885
    [18]
    马文婷. CDT-VIBE GD-EOB-DTPA增强MR诊断小肝癌的临床应用研究[D]. 兰州: 兰州大学, 2017.
    [19]
    殷婷婷, 顾 红, 杨儒牛, 等. MRI联合应用DWI和DCE扫描序列在发现肝癌切除术后肝内复发微小癌灶的价值分析[J]. 实用肝脏病杂志, 2017, 20(5): 625-6 doi: 10.3969/j.issn.1672-5069.2017.05.036
    [20]
    Powerski MJ, Scheurig-Münkler C, Hamm B, et al. Impaired hepatic Gd-EOB-DTPA enhancement after radioembolisation of liver malignancies[J]. J Med Imag Radiat Oncol, 2014, 58(4): 472-80
    [21]
    Li L, Gao F, Jiang W, et al. Folic acid-conjugated superparamagnetic Iron oxide nanoparticles for tumor-targeting Mr imaging[J]. Drug Deliv, 2016, 23(5): 1726-33
    [22]
    Moon M, Thomas RG, Heo SU, et al. A hyaluronic Acid-Conjugated Gadolinium Hepatocyte-Specific T1 contrast agent for liver magnetic resonance imaging[J]. Mol Imaging Biol, 2015, 17(4): 497-503 doi: 10.1007/s11307-014-0819-z
    [23]
    Liang J, Zhang X, Miao Y, et al. Lipid-coated Iron oxide nanoparticles for dual-modal imaging of hepatocellular carcinoma[J]. Int J Nanomedicine, 2017, 12(8): 2033-44
    [24]
    Capurro M, Wanless IR, Sherman M, et al. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma[J]. Gastroenterology, 2003, 125(1): 89-97 doi: 10.1016/S0016-5085(03)00689-9
    [25]
    Nakatsura T, Yoshitake Y, Senju S, et al. Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker[J]. Biochem Biophys Res Commun, 2003, 306(1): 16-25 doi: 10.1016/S0006-291X(03)00908-2
    [26]
    Park JO, Stephen Z, Sun C, et al. Glypican-3 targeting of liver cancer cells using multifunctional nanoparticles[J]. Mol Imaging, 2011, 10(1): 69-77
    [27]
    邝 菲, 王 飞. 氢质子磁共振波谱(1H-MRS)技术应用[J]. 医学影像学杂志, 2007, 17(8): 871-4 doi: 10.3969/j.issn.1006-9011.2007.08.034
    [28]
    Zhang L, Zhao X, Ouyang H, et al. Diagnostic value of 3.0T (1)H MRS with choline-containing compounds ratio (?CCC) in primary malignant hepatic tumors[J]. Cancer Imaging, 2016, 16(1): 25-9 doi: 10.1186/s40644-016-0082-4
    [29]
    王德清, 赵振华, 王伯胤, 等. 3.0T1H-MRS在原发性肝癌及肝脏非肝细胞癌肿瘤中的诊断价值[C]//浙江省医学会放射学学术年会, 2015: 1-4.
    [30]
    Wang JX, Merritt ME, Sherry D, et al. A general chemical shift decomposition method for hyperpolarized (13) C metabolite magnetic resonance imaging[J]. Magn Reson Chem, 2016, 54(8): 665-73 doi: 10.1002/mrc.v54.8
    [31]
    Darpolor MM, Kaplan DE, Pedersen PL, et al. Human hepatocellular carcinoma metabolism: imaging by hyperpolarized 13C magnetic resonance spectroscopy[J]. J Liver Dis Transplant, 2012, 1(1): 32-9
    [32]
    孟 俊. T2*加权与T1加权灌注成像对肝细胞癌的对比研究[D]. 川北医学院, 2013.
    [33]
    刘灿丽, 王家平, 袁曙光, 等. 磁共振灌注成像在原发性肝癌中的临床应用[J]. 放射学实践, 2010, 25(5): 519-21 doi: 10.3969/j.issn.1000-0313.2010.05.014
    [34]
    Li XH, Liang Q, Zhuang L, et al. Preliminary study of Mr diffusion tensor imaging of the liver for the diagnosis of hepatocellular carcinoma[J]. PLoS One, 2015, 10(8): e0135568-74 doi: 10.1371/journal.pone.0135568
    [35]
    Erturk SM, Ichikawa T, Kaya E, et al. Diffusion tensor imaging of cysts, hemangiomas, and metastases of the liver[J]. Acta radiol, 2014, 55(6): 654-60 doi: 10.1177/0284185113504916
    [36]
    陈丽华, 刘爱连, 宋清伟, 等. 磁共振扩散张量成像鉴别诊断肝内胆管细胞癌与肝细胞癌[J]. 中国医学影像技术, 2017, 33(7): 993-7
    [37]
    周卫兵. 磁共振扩散张量成像对肝脏病变诊断的初步研究[D]. 南昌: 南昌大学, 2011.
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (634) PDF downloads(95) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return